Prognostic significance of del(20q) in patients with hematological malignancies

被引:24
作者
Brezinová, J
Zemanová, Z
Ransdorfová, S
Sindelárová, L
Sisková, M
Neuwirtová, R
Cermák, J
Michalová, K
机构
[1] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic
[2] Charles Univ Prague, Gen Fac Hosp, Inst Clin Biochem & Lab Diagnost, Ctr Oncocytogenet, Prague, Czech Republic
[3] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
[4] Charles Univ Prague, Gen Fac Hosp, Dept Med 1, Prague, Czech Republic
[5] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
关键词
D O I
10.1016/j.cancergencyto.2004.12.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Deletions of the long arm of chromosome 20 represent a common chromosomal abnormality associated with myeloid malignancies, in particular with myeloproliferative disorders (MPD), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). Using G-banding cytogenetic techniques, we found clones with del(20q) in 36 patients with hematological malignancies examined in our laboratory during the years 2001-2003: in 23 patients as a sole cytogenetic aberration and in 13 patients together with other chromosomal changes. Fluorescence in situ hybridization (FISH) with a probe specific for the 20q12 region was used in all cases to confirm the presence of the clone with deletion. For patients with additional or complex chromosomal rearrangements, multicolor FISH (M-FISH) analysis was performed. Statistical evaluation of the prognostic impact of sex, age, diagnosis, and karyotype was performed. The survival time correlated with the type of chromosomal aberration; no significant differences in survival were found for sex, age, and diagnosis. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:188 / 192
页数:5
相关论文
共 27 条
  • [1] CLINICAL-SIGNIFICANCE OF THE DEL(20Q) CHROMOSOME IN HEMATOLOGIC DISORDERS
    AATOLA, M
    ARMSTRONG, E
    TEERENHOVI, L
    BORGSTROM, GH
    [J]. CANCER GENETICS AND CYTOGENETICS, 1992, 62 (01) : 75 - 80
  • [2] Asimakopoulos FA, 1996, BRIT J HAEMATOL, V95, P219
  • [3] MOLECULAR ANALYSIS OF CHROMOSOME 20Q DELETIONS ASSOCIATED WITH MYELOPROLIFERATIVE DISORDERS AND MYELODYSPLASTIC SYNDROMES
    ASIMAKOPOULOS, FA
    WHITE, NJ
    NACHEVA, E
    GREEN, AR
    [J]. BLOOD, 1994, 84 (09) : 3086 - 3094
  • [4] Molecular genetics and cytogenetics of myeloproliferative disorders
    Bench, AJ
    Nacheva, EP
    Champion, KM
    Green, AR
    [J]. BAILLIERES CLINICAL HAEMATOLOGY, 1998, 11 (04): : 819 - 848
  • [5] Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes
    Bench, AJ
    Nacheva, EP
    Hood, TL
    Holden, JL
    French, L
    Swanton, S
    Champion, KM
    Li, J
    Whittaker, P
    Stavrides, G
    Hunt, AR
    Huntly, BJP
    Campbell, LJ
    Bentley, DR
    Deloukas, P
    Green, AR
    [J]. ONCOGENE, 2000, 19 (34) : 3902 - 3913
  • [6] Fluorescence in situ hybridization confirmation of 5q deletions in patients with hematological malignancies
    Brezinová, J
    Zemanová, Z
    Cermák, J
    Michalová, K
    [J]. CANCER GENETICS AND CYTOGENETICS, 2000, 117 (01) : 45 - 49
  • [7] CAMPBELL LJ, 1994, LEUKEMIA, V8, P67
  • [8] Fenaux P, 1996, SEMIN HEMATOL, V33, P127
  • [9] Greenberg, 1998, BLOOD, V91, P1100
  • [10] HEIM S, 1992, CANCER, V70, P1701, DOI 10.1002/1097-0142(19920915)70:4+<1701::AID-CNCR2820701609>3.0.CO